Loa loa (African Eye Worm)

Loa loa is a thread-like filarial roundworm that lives under the skin and causes an infection called loiasis. It is far better known by its unforgettable nickname — the African eye worm — because every so often an adult worm chooses to migrate across the surface of the eye, visible and wriggling, beneath the clear membrane that covers the white of the eye. The parasite is found in the rainforests of Central and West Africa, where it is passed from person to person by the bite of a day-biting fly. For most people the illness is surprisingly mild, and the famous eye-crossing, though deeply alarming to witness, is usually harmless. Yet loiasis carries a hidden and genuinely dangerous twist: in someone whose blood is teeming with the worm's larvae, the very drugs used to treat other tropical worm diseases can trigger a severe and sometimes fatal reaction in the brain. This page explains what Loa loa is, how it spreads and lives in the body, the two hallmark signs it produces, why it complicates one of Africa's great public-health campaigns, and how it is diagnosed, treated, and prevented.

Table of Contents

  1. What Is Loa loa?
  2. The Parasite and Its Life Cycle
  3. Symptoms and Disease
  4. The Key Treatment Danger
  5. Who Is at Risk and Where It Occurs
  6. Diagnosis
  7. Treatment
  8. Prevention
  9. Key Research Papers
  10. Connections
  11. Featured Videos

1. What Is Loa loa?

Loa loa is a filarial roundworm — a member of the same broad family of thread-like parasites that cause river blindness and lymphatic filariasis (elephantiasis). The word "filarial" simply means these worms are long and slender, like a thread or a fine filament. The disease Loa loa causes is called loiasis, and its most famous common name, the African eye worm, comes from the parasite's occasional habit of crawling across the eye where anyone can see it.

Unlike a bacterium or a virus, Loa loa is a true animal — a nematode, or roundworm. The adult worms are pale and thread-fine, with the females growing to several centimeters long, and they live in the loose tissue just beneath the skin, drifting slowly from place to place. The infection is confined to the equatorial rainforest belt of Central and West Africa, and it is common: several million people are thought to be infected.

What sets loiasis apart is a striking contradiction. For the person carrying the worms, the illness is often mild — sometimes causing no symptoms at all — and even the dramatic eye-crossing usually does no lasting harm. Yet from a public-health standpoint, Loa loa is anything but trivial. In parts of Africa it stands directly in the way of the mass drug campaigns that have nearly eliminated river blindness elsewhere, because of a dangerous reaction those campaigns can provoke in heavily infected people. The sections below trace both sides of that story.

2. The Parasite and Its Life Cycle

Loiasis is spread not by mosquitoes but by the bite of a large, day-biting fly of the genus Chrysops — known variously as deer flies, mango flies, or red flies. These flies breed in the muddy margins of shaded forest streams and bite during daylight hours, often drawn to movement and to the smoke of cooking fires. This daytime biting habit is a crucial detail, as we will see, because the parasite has evolved its whole rhythm around it.

When an infected Chrysops fly bites, it deposits immature worm larvae onto the skin, and these wriggle into the bite wound. Over the following months the larvae slowly mature into adult worms that take up residence in the subcutaneous tissue — the soft layer just under the skin. The adults are remarkably long-lived, surviving and roaming in the body for many years, and they migrate through the tissues at a slow but steady creep. It is this wandering that produces the disease's two signature signs: fleeting swellings where a worm passes, and the occasional unforgettable journey across the eye.

Once mated, the female worms release enormous numbers of tiny offspring called microfilariae, which enter the bloodstream and circulate through the body. Here the parasite reveals a beautiful piece of evolutionary timing. The microfilariae are not present in the blood at all hours; instead they surge into the circulation during the middle of the day and retreat into the small vessels of the lungs at night — a pattern called diurnal periodicity. Their peak, around the middle of the day, coincides exactly with the biting hours of the Chrysops fly. When a fly takes a daytime blood meal, it swallows the circulating microfilariae; inside the fly they develop into infectious larvae over one to two weeks, and the next bite passes them to a new person, completing the cycle. Humans are the parasite's main host.

3. Symptoms and Disease

For a great many people, loiasis is mild or even silent. Long-term residents of endemic areas may carry the worms for years with few complaints, discovering the infection only when microfilariae turn up on a blood test done for another reason. When the infection does announce itself, it usually does so through two hallmark signs, both caused by the adult worms wandering through the body.

Calabar swellings

The first hallmark is the Calabar swelling — named after the Nigerian port town of Calabar, where the sign was first well described. These are transient, localized, itchy swellings that appear suddenly, most often on the wrists, forearms, or near a joint, and then fade over hours to a few days before turning up somewhere else. They are not the worm itself but an allergic reaction to a worm moving nearby, and they can be uncomfortable and intermittently recurring over years. In travelers and visitors especially, these swellings are often the most prominent feature of the illness.

The eye worm

The second hallmark is the one that gives the parasite its name: the adult worm migrating across the eye. Every so often a worm travels beneath the thin, clear membrane (the conjunctiva) that covers the white of the eye, and for a few minutes to a few hours it is plainly visible, wriggling across the surface. The experience is intensely alarming — and often accompanied by pain, tearing, redness, and a feeling of something crawling — but it is usually harmless, causing no lasting damage to vision. The worm generally moves on within hours.

Other symptoms

Beyond these two signs, people may report generalized itching, hives, and joint and muscle aches, along with fatigue. Blood tests very commonly show a high count of a white blood cell called the eosinophil (eosinophilia), a typical fingerprint of parasitic worm infection. Serious complications — affecting the kidneys, heart, or nervous system — are uncommon but can occur, particularly when microfilariae are extremely numerous. Loiasis was long regarded as an essentially benign nuisance, but more recent research suggests that very heavy infections may carry real risks to health, a point revisited below.

4. The Key Treatment Danger

This is the most important section on the page, and it is worth stating plainly. In a person whose blood carries a very high load of Loa loa microfilariae, giving one of the standard anti-worm drugs — ivermectin or diethylcarbamazine (DEC) — can trigger a severe reaction in the brain (encephalopathy) that is sometimes fatal. The likely mechanism is straightforward and grim: the drug kills huge numbers of microfilariae almost at once, and the sudden mass death of parasites in the small vessels of the brain provokes a catastrophic inflammatory reaction. The result can be confusion, coma, and death within days of a single dose.

This is not a rare theoretical worry — it is the central problem Loa loa poses to public health in Central Africa. Across much of the continent, mass drug campaigns hand out ivermectin to entire communities to control river blindness (onchocerciasis) and lymphatic filariasis, and these campaigns have been enormously successful. But in the regions where those diseases overlap with loiasis, a person who happens to be carrying an intense Loa loa infection can suffer a serious, occasionally fatal reaction after swallowing a single tablet meant to help them. The problem was brought sharply into focus by a landmark 1997 report in The Lancet documenting serious neurological reactions after ivermectin treatment in a Loa loa–endemic area of Cameroon.

The danger rises steeply with the number of microfilariae in the blood. Serious reactions become a real concern once counts climb into the tens of thousands of microfilariae per milliliter, and the highest risk is seen at the most extreme loads — above roughly 30,000 to 50,000 microfilariae per milliliter. This is precisely why screening a person's microfilarial load matters before treatment. A modern solution, tested in a large Cameroon study, is a “test-and-not-treat” strategy: a quick point-of-care test (such as a smartphone-based video microscope) measures each person's microfilarial count on the spot, and ivermectin is withheld from the small number of people whose counts are dangerously high — roughly above 20,000 per milliliter — allowing everyone else to be treated safely. The takeaway for any individual is simple: loiasis treatment should never be improvised, and drugs that clear related worms are not automatically safe when Loa loa is in the picture.

5. Who Is at Risk and Where It Occurs

Loiasis is confined to the rainforest and forest-savanna zones of Central and West Africa. The core endemic countries include Cameroon, Gabon, the Republic of the Congo, the Democratic Republic of the Congo, the Central African Republic, Equatorial Guinea, Nigeria, southern Chad, and Angola, with the heaviest transmission in humid, forested country where the Chrysops flies thrive. Large mapping efforts — using a simple questionnaire that asks people whether they have ever seen a worm cross their eye — have charted where the parasite is common, information that is essential for planning safe drug campaigns.

The greatest risk falls on people who live and work in or near the rainforest, where daily exposure to biting flies is unavoidable. Interestingly, the disease often looks quite different in two kinds of people:

For years loiasis was filed away as a benign curiosity, but that view has been challenged. A large cohort study found evidence that people with high microfilarial loads have higher-than-expected mortality, suggesting the infection may quietly carry more health burden than its usually mild symptoms imply. This is an active area of research rather than a settled fact, but it is a reason to take heavy infections seriously.

6. Diagnosis

Because the parasite has its own daily rhythm, the timing of testing is everything. The most direct way to confirm loiasis is to find the microfilariae on a blood smear — but the blood must be drawn during the daytime, ideally around the middle of the day (roughly 10 a.m. to 2 p.m.), when the microfilariae surge into the circulation. A stained thick blood film is examined under the microscope, and the number of microfilariae can be counted to estimate the load, a figure that directly informs how safely the person can be treated.

An even more definitive proof is simply seeing or removing an adult worm — catching one as it crosses the eye, or extracting one from beneath the skin. This is unambiguous, though it depends on being in the right place at the right moment.

Diagnosis is trickier in travelers and expatriates, who often have symptoms but no detectable microfilariae in the blood. Here doctors rely on supporting clues — a compatible history of forest exposure, recurrent Calabar swellings, a high eosinophil count, and raised antibody levels — together with serology (antibody blood tests), keeping in mind that antibody tests can cross-react with other filarial worms and cannot always tell them apart. One important laboratory caution is that a very high Loa loa microfilarial load can cause false-positive results on the rapid antigen tests used to diagnose lymphatic filariasis, a pitfall that matters when the two infections share the same regions. Molecular (DNA) tests and newer field devices that count microfilariae rapidly are increasingly used to sharpen and speed the diagnosis.

7. Treatment

Loiasis can be cured, but because of the encephalopathy danger described above, treatment belongs firmly in the hands of specialists in tropical or infectious disease and must be matched to the person's microfilarial load. The following describes what is typically reported in the medical literature, not a self-treatment guide.

The one drug that can actually cure the infection — killing both the adult worms and the microfilariae — is diethylcarbamazine (DEC). It is the cornerstone of treatment and often needs to be given as more than one course to clear the worms fully. Its great drawback is that, like ivermectin, DEC can provoke a severe reaction when microfilariae are very numerous, so it is used cautiously and its dose is often escalated slowly.

To make treatment safer, clinicians frequently use albendazole first. Albendazole lowers the microfilarial count slowly and gently over weeks, without the sudden mass die-off that causes trouble, so that once the load has fallen, curative treatment with DEC can be given with far less risk. Ivermectin reduces microfilariae effectively but does not kill the adult worms, and it carries the same high-load danger; it is used in selected situations. In the most extreme cases, doctors have used apheresis — a procedure that physically filters microfilariae out of the blood — to bring counts down before starting drug treatment. Surgically removing a worm from the eye or skin gives immediate, satisfying relief from that particular worm, but it does not cure the underlying infection, which requires medication. Comparative studies confirm that DEC-based regimens achieve the best cure rates, while reinforcing that the whole process must be managed carefully.

8. Prevention

There is no vaccine against loiasis, so prevention rests on avoiding the bite of the Chrysops fly. Because these flies bite during the day, near forest and around rubber and other plantations, and are attracted to movement and woodsmoke, the practical protections are the familiar ones for daytime biting insects:

For long-term travelers and expatriates heading into heavily endemic forest, a doctor may recommend DEC taken preventively (a common regimen is a weekly dose) to lower the chance of infection — a decision that should be made with a travel-medicine or tropical-disease specialist. Controlling the flies themselves is difficult, because they breed in inaccessible forest streams, so for people who live in endemic regions, personal protection against bites remains the mainstay. And for anyone who has spent time in the loiasis belt and later needs treatment for another filarial disease, the single most important safeguard is to make sure their Loa loa status and microfilarial load are checked first, so that treatment can be given safely.

Key Research Papers

Peer-reviewed reviews and clinical studies on Loa loa and loiasis — covering the parasite's biology and geography, the two hallmark signs, the serious reactions that follow drug treatment in heavily infected people, and how the infection is diagnosed and cured. Journal names appear as plain text; the year/volume/pages link opens the full citation via DOI.

  1. Gardon J, Gardon-Wendel N, Demanga-Ngangue, Kamgno J, Chippaux JP, Boussinesq M. Serious Reactions After Mass Treatment of Onchocerciasis with Ivermectin in an Area Endemic for Loa loa Infection. Lancet. 1997;350(9070):18–22.
  2. Boussinesq M. Loiasis. Annals of Tropical Medicine & Parasitology. 2006;100(8):715–731.
  3. Metzger WG, Mordmüller B. Loa loa—Does It Deserve to Be Neglected? Lancet Infectious Diseases. 2014;14(4):353–357.
  4. Klion AD, Massougbodji A, Sadeler BC, Ottesen EA, Nutman TB. Loiasis in Endemic and Nonendemic Populations: Immunologically Mediated Differences in Clinical Presentation. Journal of Infectious Diseases. 1991;163(6):1318–1325.
  5. Kamgno J, Pion SD, Chesnais CB, et al. A Test-and-Not-Treat Strategy for Onchocerciasis in Loa loa–Endemic Areas. New England Journal of Medicine. 2017;377(21):2044–2052.
  6. Zouré HGM, Wanji S, Noma M, et al. The Geographic Distribution of Loa loa in Africa: Results of Large-Scale Implementation of the Rapid Assessment Procedure for Loiasis (RAPLOA). PLoS Neglected Tropical Diseases. 2011;5(6):e1210.
  7. Chesnais CB, Takougang I, Paguélé M, Pion SD, Boussinesq M. Excess Mortality Associated with Loiasis: A Retrospective Cohort Study. Lancet Infectious Diseases. 2017;17(1):108–116.
  8. Herrick JA, Legrand F, Gounoue R, et al. Posttreatment Reactions After Single-Dose Diethylcarbamazine or Ivermectin in Subjects with Loa loa Infection. Clinical Infectious Diseases. 2017;64(8):1017–1025.
  9. Pion SD, Montavon C, Chesnais CB, et al. Positivity of Antigen Tests Used for Diagnosis of Lymphatic Filariasis in Individuals Without Wuchereria bancrofti Infection But with High Loa loa Microfilaremia. American Journal of Tropical Medicine and Hygiene. 2016;95(6):1417–1423.
  10. Gobbi F, Bottieau E, Bisoffi Z, et al. Comparison of Different Drug Regimens for the Treatment of Loiasis—A TropNet Retrospective Study. PLoS Neglected Tropical Diseases. 2018;12(11):e0006917.
  11. Tabi TE, Befidi-Mengue R, Nutman TB, et al. Human Loiasis in a Cameroonian Village: A Double-Blind, Placebo-Controlled, Crossover Clinical Trial of a Three-Day Albendazole Regimen. American Journal of Tropical Medicine and Hygiene. 2004;71(2):211–215.
  12. Klion AD, Ottesen EA, Nutman TB. Effectiveness of Diethylcarbamazine in Treating Loiasis Acquired by Expatriate Visitors to Endemic Regions: Long-Term Follow-Up. Journal of Infectious Diseases. 1994;169(3):604–610.

Live PubMed Searches

Each link opens a live PubMed query so results stay current as new papers are indexed.

  1. Loa loa loiasis
  2. Loa loa ivermectin encephalopathy
  3. Loiasis Calabar swellings
  4. Loa loa Chrysops transmission
  5. Loiasis diethylcarbamazine treatment
  6. Loa loa microfilaremia adverse events
  7. Test-and-not-treat onchocerciasis Loa loa
  8. Loa loa albendazole and apheresis

Back to Table of Contents

Connections

Back to Table of Contents